AngioDesign

AngioDesign is a private, preclinical-stage biotech leveraging unique structural biology insights to develop next-generation, domain-selective ACE inhibitors. The company's founders were instrumental in solving the first high-resolution crystal structure of ACE, providing a foundation for designing drugs that aim to retain the cardiovascular benefits of traditional ACE inhibitors while mitigating common side effects like cough and angioedema. Its lead strategy involves developing first-in-class dual C-domain ACE/NEP inhibitors for hypertension and heart failure, targeting a blockbuster market with significant unmet need. The company operates with a lean management model and holds full ownership of its core intellectual property.

3-D structure-guided rational drug design platform focused on creating domain-selective inhibitors of Angiotensin-Converting Enzyme (ACE). Leverages proprietary high-resolution crystal structures of ACE's N- and C-domains to design small molecules that selectively target one domain to improve therapeutic index.

AngioDesign competes in the crowded cardiovascular space against generic ACE inhibitors, ARBs, beta-blockers, and newer branded drug classes like ARNIs (e.g., sacubitril/valsartan). Its differentiation hinges on domain-selectivity, a novel approach not yet validated in approved drugs. It faces competition from large pharma with extensive cardiovascular portfolios and significant commercial resources.